INTERACT Applauds NCCN's Updated Guidelines for Genetic Testing Access in Hereditary Cancer Risk
INTERACT Applauds NCCN's Updated Guidelines for Genetic Testing Access in Hereditary Cancer Risk
The Inter-Organization Cancer Genetics Clinical Evidence Coalition, widely known as INTERACT, has expressed strong approval for the latest updates provided by the National Comprehensive Cancer Network (NCCN). The updated guidelines focus on Genetic/Familial High-Risk Assessment for various cancers, including colorectal, endometrial, esophageal, gastric, neuroendocrine, and adrenal tumors. This substantial change marks a step forward in helping individuals understand their hereditary cancer risks and expands access to evidence-based genetic testing for affected families and patients.
Hereditary cancer genetic testing is essential for identifying individuals who may possess inherited predispositions to various cancers. Early identification allows patients and their families to engage in tailored surveillance and consider preventive measures. In some cases, it can also guide targeted therapies that notably improve health outcomes. As the NCCN updates its guidelines, it continues to support broader recommendations that will enable more patients to obtain the crucial genetic knowledge required to make informed decisions regarding their treatment, cancer surveillance, and preventive healthcare.
Key Updates in the New Guidelines
A few key highlights from the revised guidelines include:
1. Expanded Access for Colorectal and Endometrial Cancer Patients: The guidelines now recommend multigene panel testing (MGPT) for all patients diagnosed with colorectal or endometrial cancer, regardless of their age or family history.
2. Broader Testing for Gastric Cancer Patients: Similar to colorectal and endometrial cancer, the guidelines advocate for MGPT for every individual diagnosed with gastric cancer, irrespective of age or family medical history.
3. Inclusion of Esophageal Cancer Recommendations: The updates to the guidelines also cover esophageal cancer, which includes new recommendations for screening and risk evaluation.
4. Early Genetic Testing: The revised guidelines emphasize the importance of earlier genetic testing within the patient care journey. This approach promotes the initiation of MGPT as the preferred method, suggesting that testing should not be delayed due to the wait for tumor screening results.
5. Focused Assessment in Neuroendocrine and Adrenal Tumors: New sections within the guidelines spotlight the necessity of genetic counseling for neuroendocrine and adrenal tumors, advocating for germline testing and tailored surveillance for these specific cancers.
6. Inclusive Recommendations for Thymic Neuroendocrine Tumors: The guidelines now advise considering genetic risk evaluation for patients diagnosed with thymic neuroendocrine tumors at any age.
The NCCN Guidelines have earned a reputation as the gold standard for clinical decisions within oncology. These comprehensive recommendations are constructed by multidisciplinary groups of experts who guide patient care, outline clinical workflows, and determine insurance coverage policies throughout the United States.
Lisa Schlager, the Vice President of Public Policy for FORCE Facing Our Risk of Cancer Empowered, expressed her encouragement regarding the NCCN’s commitment to refining its guidelines according to the expanding body of evidence supporting broader access to genetic testing. This sentiment is echoed by Robin Dubin, Executive Director of AliveandKick’n, who highlighted that earlier testing could be instrumental in identifying hereditary risks before they escalate, thus improving opportunities for early intervention and better treatment outcomes.
About INTERACT
INTERACT is a coalition focused on promoting evidence-based access to genetic testing aimed at individuals with, or at risk of, hereditary cancers. By advocating for these updates, the coalition strives to enhance outcomes through early detection, targeted interventions, and informed risk assessments within families. The coalition is made up of leading industry organizations including Ambry Genetics, Illumina, Myriad Genetics, Natera, Quest Diagnostics, and My Gene Counsel. Furthermore, it aligns with various patient advocacy groups that support equitable access to genetic testing while championing clinical guidelines that are consistent with current scientific evidence.
This collaborative effort within the INTERACT coalition exemplifies a commitment to ensuring that individuals and families have the genetic insights needed to manage hereditary cancer risks effectively. As the landscape of genetic testing evolves, initiatives like these will continue to drive fundamental improvements in healthcare outcomes for many families affected by hereditary cancers.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.